|
Título:
|
Rapid responses to the COVID-19 pandemic through science and global collaboration: The solidarity clinical trial
|
|
Autores:
|
Soto, A. ;
Quiñones-Laveriano, D.M. ;
Garcia, P.J. ;
Gotuzzo, E. ;
Henao-Restrepo, A.M.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Instituto Nacional de Salud, 2020-12-14T16:11:19Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Español
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
COVID-19 represents a global crisis. Rapidly conducting a clinical trial with the rigor necessary to obtain reliable results requires the collaboration of various participants involved in the development, evaluation and authorization of clinical trials (CT) such as the trial sponsor, researchers, regulatory authority and the ethics committee (EC). Carrying out these studies is not only scientifically appropriate, but an ethical and moral obligation to guarantee our patients effective treatment. SOLIDARITY is a mega clinical trial that recruited thousands of subjects with moderate to severe disease, who were randomly assigned to one of the treatment groups under evaluation, including hydroxychloroquine, lopinavir/ritonavir associated or not with interferon; or remdesivir compared to standard therapy. Peru has joined the list of countries where the trial will be reproduced, through which it will be possible to quickly identify if any of these drugs offers a real benefit to patients. © 2020, Instituto Nacional de Salud. All rights reserved.
|
|
En línea:
|
http://repositorio.upch.edu.pe/handle/upch/8903
|
